Shire little moved after EU approval of Xagrid drug

LONDON (CBS.MW) -- Shire Pharmaceuticals
shpgySHP, +1.58%
was little changed in afternoon London trade amid saying it received approval for Xagrid for second line, monotherapy treatment of a bone marrow disorder in the European Union, Iceland and Norway. Shire will have a phased launch throughout Europe and expects the drug to be available for prescribing from the new year. The drug is sold in the U.S. and other countries under either the Agrylin or Xagrid name and had 2003 sales of $132.5 million.

Have breaking news sent to your inbox. Subscribe to MarketWatch's free Bulletin emails. Sign up here.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.